Allspring Global Investments Holdings LLC Lowers Holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Allspring Global Investments Holdings LLC decreased its stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) by 4.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 130,189 shares of the biotechnology company’s stock after selling 6,608 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.43% of Alpine Immune Sciences worth $937,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Lazard Asset Management LLC purchased a new position in shares of Alpine Immune Sciences in the second quarter worth $39,000. American International Group Inc. raised its stake in shares of Alpine Immune Sciences by 26.8% in the second quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,543 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Alpine Immune Sciences by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,697 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Alpine Immune Sciences by 212.3% in the first quarter. Bank of America Corp DE now owns 15,442 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 10,498 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Alpine Immune Sciences in the second quarter worth $174,000.

Alpine Immune Sciences Stock Performance

NASDAQ:ALPN opened at $8.63 on Friday. The stock has a 50-day simple moving average of $6.95 and a two-hundred day simple moving average of $7.37. Alpine Immune Sciences, Inc. has a 52-week low of $4.82 and a 52-week high of $10.30. The firm has a market capitalization of $262.36 million, a PE ratio of -4.82 and a beta of 1.28.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last released its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.32). Alpine Immune Sciences had a negative net margin of 169.92% and a negative return on equity of 41.76%. The company had revenue of $8.37 million for the quarter, compared to the consensus estimate of $20.43 million. Equities analysts forecast that Alpine Immune Sciences, Inc. will post -1.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ALPN has been the subject of several recent analyst reports. HC Wainwright decreased their price target on Alpine Immune Sciences from $21.00 to $8.00 in a research note on Monday, October 24th. Morgan Stanley started coverage on Alpine Immune Sciences in a research report on Thursday. They set an “overweight” rating and a $17.00 price objective for the company. SVB Leerink started coverage on Alpine Immune Sciences in a research report on Monday, November 21st. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Oppenheimer reduced their price objective on Alpine Immune Sciences from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, October 24th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Alpine Immune Sciences presently has a consensus rating of “Buy” and an average price target of $15.80.

About Alpine Immune Sciences

(Get Rating)

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.